Free Newsletter
City to sue Merck, Schering-Plough
The city of New Haven, Connecticut will be suing Merck and Schering-Plough on the basis that Vyotrin doesn't work.
New Haven, which has spent $100,000 shy of a half million dollars on Vytorin and Zetia for employees, will seek reimbursement for the tax money it spent on the medications.
While Merck did not comment, a Schering-Plough spokesperson said the company stood behind its product and would fight any challenge vigorously.
- check out the Pharmalot blog entry
Related Articles:
Analyst gloomy on Merck trends
Congress broadens Vytorin probe
Merck, Schering-Plough stocks take a dive
More bad Vytorin news for Merck, Schering
Vytorin scrips still falling, Hassan hires help
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: